Artelo Biosciences (ARTL) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Jun, 2026Voting matters and shareholder proposals
Election of three directors: Gregory R. Reyes, M.D., Ph.D., Tamara A. Favorito, and Gregory D. Gorgas, all recommended by the board for election.
Proposal to amend the Articles of Incorporation to increase authorized common stock from 166,666,667 to 500,000,000 shares.
Proxyholders have discretion to vote on other business that may arise at the meeting or any adjournment.
Shareholder rights and capital structure
Shareholders are asked to approve a significant increase in authorized common stock, potentially impacting future capital raising and dilution.
Board of directors and corporate governance
Board recommends all director nominees for election at the annual meeting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Artelo Biosciences
- Multiple clinical milestones expected in the next 18 months across a diverse therapeutic pipeline.ARTL
H.C. Wainwright 26th Annual Global Investment Conference 202430 Jun 2026 - Shareholders will vote on director elections, a large share increase, and a major equity issuance.ARTL
Proxy filing22 Jun 2026 - Lead drug candidates advance in cancer, pain, and anxiety with strong safety and efficacy data.ARTL
Corporate presentation5 Jun 2026 - Shareholders will vote on director elections and a major increase in authorized common stock.ARTL
Proxy filing5 Jun 2026 - Lead drug candidates show strong progress in major markets with robust safety and efficacy data.ARTL
Corporate presentation26 May 2026 - Shareholders will vote on director elections and a major increase in authorized common stock.ARTL
Proxy filing26 May 2026 - Q1 2026 net loss reached $3.0M; cash at $10.3M after $10M financing, but going concern risk remains.ARTL
Q1 202615 May 2026 - Advancing novel lipid signaling drugs with strong clinical data and large market potential.ARTL
Corporate presentation14 May 2026 - Shelf registration allows flexible securities offerings with strong management indemnification.ARTL
Registration filing14 May 2026